Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19
Shaikh, Y.; Gupta, I.; Purekal, S.; Vaeth, M. E.; Foyez, M.; Callahan, C. D.; Elhabashy, M.; Ficke, J. R.; Wu, A. W.; Auwaerter, P.; Kantsiper, M. E.; Siddiqui, Z. K.
Show abstract
Background and MethodsWe conducted a single center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021 and May 14, 2021. ResultsAmong the 2,406 eligible participants, African Americans were significantly more likely to underutilize mAb treatment (OR 1.8; 95% CI 1.5-2.1) and miss treatment opportunities due to monoclonal hesitancy (OR 1.7, 95% CI 1.3-2.1). ConclusionAddressing racial disparities in mAb delivery is an opportunity to bridge the racial inequities in COVID-19 care.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial 93%
- The Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients 90%
- Out-of-Pocket Spending for COVID-19 Hospitalizations in 2020 90%
Similar papers in this journal
- Impact of monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection 94%
- Sex and gender differences in COVID testing, hospital admission, presentation, and drivers of severe outcomes in the DC/Maryland region 91%
- HIV Treatment Outcomes In Rural Georgia Using Telemedicine 90%
Similar papers in this journal
- Clinical Trends Among U.S. Adults Hospitalized with COVID-19, March-December 2020 91%
- Assessment of COVID-19 vaccine acceptance among healthcare workers in Los Angeles 90%
- Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes 88%
Similar papers in this journal
- “All of the things to everyone everywhere”: A mixed methods analysis of community perspectives on equitable access to monoclonal antibody treatment for COVID-19 94%
- Clinical Characteristics and Outcomes for 7,995 Patients with SARS-CoV-2 Infection 91%
- Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system 91%
Similar papers in this journal
- A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients 93%
- Characteristics and Factors Associated with COVID-19 Infection, Hospitalization, and Mortality Across Race and Ethnicity 92%
- Compassionate Use of REGEN-COV ® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.